Skip to content

ESD Home

TechCentury

Powered by

Engineering Society of Detroit Lawrence Technological University

Tag: Bempedoic Acid

Pharmaceuticals

Esperion expands licensing deal with Daiichi Sankyo Group

Esperion expands partnership with Daiichi Sankyo Group ANN ARBOR–Esperion Therapeutics (NASDAQ: ESPR), developers of a new class of cholesterol-lowering drugs, announced it has entered into a licensing agreement with Daiichi …

Pharmaceuticals

New cholesterol-buster from Esperion now available in U.S.

ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), developers of novel treatments to reduce cholesterol in the bloodstream, announced the United States commercial availability of Nexlizet tablets. Nexlizet is a combination of …

Pharmaceuticals

Esperion gets Japanese manufacturer for new cholesterol-buster

ANN ARBOR—Esperion Therapeutics Inc. announced a collaboration agreement with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of Nexletol and Nexlizet tablets in Japan.  Both medicines were recently approved …

Pharmaceuticals

Esperion cholesterol-buster gets European OK

ANN ARBOR—The European Commission has approved the sale of new cholesterol-lowering drugs from Ann Arbor-based Esperion Therapeutics Inc. (Nasdaq: ESPR). Approved were Nilemdo, a tablet containing the new drug bempedoic …

Pharmaceuticals / Startups

Esperion gets FDA OK for another new cholesterol-buster, offers financial update

ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced U.S. Food and Drug Administration approval of Nexlizet, a combination tablet of Esperion’s new non-statin cholesterol reducing drug bempedoic acid and an earlier …

Pharmaceuticals / Startups

Esperion wins FDA approval for new cholesterol-buster, Nexletol

ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) announced that the U.S. Food and Drug Administration (FDA) approved Nexletol (bempedoic acid) tablet, an oral, once-daily, non-statin cholesterol-lowering medicine. Nexletol is indicated as an …

Pharmaceuticals / Startups

Another step toward European OK for Esperion cholesterol drugs

ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a “positive opinion” for both its bempedoic …

Clinical Trials / Pharmaceuticals

Esperion drug candidate named top innovation of 2020

ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based pharmaceutical startup developing a new class of cholesterol-fighting drugs, announced that its lead drug candidate, bempedoic acid, was included in the …

Clinical Trials / Pharmaceuticals / Startups

Good news on latest trial of Esperion cholesterol-buster

ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), the Ann Arbor pharma startup developing a new class of cholesterol-fighting drugs, announced positive top-line results from a Phase 2 clinical study of its combination …

Earnings / Pharmaceuticals

Esperion has cash to last until new cholesterol drug produces profits

ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR), the Ann Arbor-based pharmaceutical startup that’s about to introduce a new class of cholesterol-fighting drugs, reported a loss of $54.2 million or $2.01 a share …

Posts navigation

Older posts

Read the magazine:

TechCentury
Advertise or Contribute an Article

Subscribe to TechCentury.com

Top Posts

  • Our Next Energy raises $300 million in Series B
  • Full STEM ahead: Oakland Schools show off new mobile classroom
  • New LTU-EGLE program taps retired professionals' skills to boost sustainability
  • AdAdapted names senior VP of marketing
  • Teams from Rochester, Ann Arbor headed to Future City finals in DC

Archives

Follow Us On

© The Engineering Society of Detroit   |   ABOUT